Cantor Fitzgerald Sets Ambitious $700 Price Target for AMD, Citing Dominance in AI Chip Race
Money

Cantor Fitzgerald Sets Ambitious $700 Price Target for AMD, Citing Dominance in AI Chip Race

authorBy Scott Pape
DateJul 05, 2026
Read Time4 min
This article examines a significant shift in Wall Street's perception of Advanced Micro Devices (AMD), highlighting an analyst's remarkably optimistic price target and the underlying factors driving this confidence in the burgeoning AI chip market.

Wall Street's New Favorite: A Bold Bet on AMD's Future

Analyst Raises AMD Price Target to $700 Amidst AI Chip Enthusiasm

A prominent analyst from Cantor Fitzgerald, C.J. Muse, has made a striking adjustment to his price target for Advanced Micro Devices (AMD), elevating it from $500 to an unprecedented $700. This revised forecast, issued on June 29, maintains an 'Overweight' rating for the semiconductor giant, signaling a strong belief in its future performance. This makes Cantor Fitzgerald's target the most bullish on Wall Street for AMD.

AMD Outpaces Rivals: Named Top Pick in Computing Sector

Cantor Fitzgerald's latest assessment positions AMD as the premier choice within the computing sector, surpassing industry heavyweights such as Nvidia and Broadcom. This endorsement underscores a growing recognition of AMD's accelerating progress and competitive edge in the rapidly evolving AI chip landscape. The analyst's high praise suggests a potential reordering of market leadership in this critical technology segment.

Market Volatility and Analyst Conviction: AMD's Recent Performance

The timing of this elevated price target is particularly noteworthy. AMD shares reached a record high of $580.91 on June 30, marking an impressive year-to-date gain exceeding 150%. However, the stock experienced a nearly 7% decline in the subsequent trading session, following reports that Meta Platforms might begin reselling its surplus AI computing capacity. Despite this brief downturn, Muse's $700 target still projects a more than 34% increase from the stock's trading levels that week, indicating strong conviction in AMD's long-term trajectory.

Cantor Fitzgerald's Rationale: AMD's Momentum in the Computing Market

C.J. Muse asserts that AMD is currently demonstrating the most significant momentum among semiconductor companies in the computing market. While acknowledging that Qualcomm's recent push into chip development is likely to remain primarily focused on smartphones, Muse still views Nvidia and Broadcom as reasonably valued, even with their recent fluctuations. The sustained 'Overweight' rating for AMD, even with the higher target, reinforces the analyst's positive outlook.

Widespread Optimism: Other Analysts Follow with Increased Targets

Cantor Fitzgerald is not alone in its bullish stance. UBS analyst Timothy Arcuri set a $670 target in the same week, while Wells Fargo's Aaron Rakers increased his to $615. Wells Fargo's analysis specifically highlights AMD's less-publicized server CPU business, rather than its GPU offerings, as a key driver for its optimistic outlook. These various perspectives collectively point to a common theme: both server processors and AI accelerators are fueling a substantial data-center boom, benefiting AMD.

AMD's Data Center Dominance: A Foundation for Growth

AMD's financial results provide concrete backing for these elevated expectations. The company reported first-quarter revenue of $10.3 billion, with a gross margin of 53% and diluted earnings per share of 84 cents. Crucially, data center sales surged by 57% to $5.8 billion, now accounting for over half of AMD's total revenue. CEO Dr. Lisa Su has attributed this growth to robust demand for high-performance chips, driven by the expanding use of AI inferencing and autonomous AI agents.

Strategic Deployments and Customer Engagement Fueling Expansion

Two recent developments further illustrate AMD's strong position. The company's newest server chips, the sixth-generation EPYC Venice line, commenced production scaling in May. AMD notes that more customers are currently testing this generation of server chips than any preceding EPYC launch, indicating strong market acceptance. Additionally, AMD finalized an agreement with Rackspace Technology on June 16 to provide 30 megawatts of AI computing power, with deployment scheduled to continue in phases through 2028.

The Path to $700: Overcoming Skepticism and Bridging the Valuation Gap

Despite the strong analyst support, Wall Street's average price target for AMD remains at $509.75, significantly below Cantor's ambitious projection and even the stock's recent trading range. The wide spread in price targets, from $250 to $700 across 35 analysts, reflects considerable market uncertainty. A stock trading at approximately 70 times its projected earnings provides ample justification for skeptics. Furthermore, Meta's potential entry into reselling excess AI computing capacity adds another layer of unpredictability. Nevertheless, D.A. Davidson analyst Gil Luria maintains a 'Buy' rating, arguing that the demand for AI computing continues to outstrip supply, irrespective of recent market noise. For AMD to reach the $700 mark, sustained data center revenue growth above 50% as Venice server chips scale through 2026 and 2027 will be crucial. Timely and successful deployment of hyperscaler agreements, such as the Rackspace deal, is also vital. Furthermore, AI chip demand must remain robust, even if cloud giants begin reselling spare capacity. Finally, the average Wall Street target needs to converge with Cantor's outlier call. Cantor Fitzgerald stands as the most optimistic voice on Wall Street, wagering that AMD's computing momentum still has substantial room for growth. Whether the rest of Wall Street aligns with this view will likely depend on AMD's server CPU business performance when the company announces its second-quarter results in early August.

More Articles
Money
Hedge Fund Divests Significant Stake in Establishment Labs Amidst Strong Performance
JW Asset Management, a hedge fund, recently sold 90,533 shares of Establishment Labs Holdings Inc. for approximately $6.64 million. Despite this substantial divestment, the fund retains a significant holding, indicating continued bullish sentiment. This transaction occurred as Establishment Labs experienced robust revenue growth and inclusion in the Russell 2000 Index, driving its stock to a 52-week high.
By Ramit SethiJul 05, 2026
Money
Petco's Strategic Revival: A Promising Prospect for Value Investors
Petco Health and Wellness Company Inc. (NASDAQ: WOOF) has demonstrated a robust financial rebound in FQ1 2026, driven by its "Reach for the Sky" strategy. The company reported positive comparable sales growth and improved profitability, making it an attractive value penny stock according to hedge funds. With reduced debt and a maintained full-year outlook, Petco aims to strengthen its market position in pet products and services.
By JL CollinsJul 05, 2026
Money
NIO's Strong Delivery Growth and Market Performance in Q2 2026
NIO Inc. announced robust delivery figures for June and the second quarter of 2026, with vehicle deliveries increasing by 62.9% year-over-year. The company's innovative product launches and intelligent driving system upgrades contributed to this growth, even as its stock experienced a slight dip year-to-date. This report delves into NIO's operational achievements and market standing.
By JL CollinsJul 05, 2026
Money
Goldman Sachs Endorses Braze: A Leader in AI-Powered Marketing
Goldman Sachs has issued a 'Buy' rating for Braze, Inc. (BRZE), recognizing its robust position to outcompete traditional marketing platforms. This endorsement follows a period of accelerated growth for Braze, an AI-driven customer engagement solution. The firm projects Braze will achieve a 20% operating margin by 2029, highlighting its innovative approach to sophisticated campaign orchestration amidst rising customer expectations and increasing pressure on outdated technologies.
By Dave RamseyJul 05, 2026
Money
Leerink: Altimmune an Attractive Opportunity in MASH Therapy
Leerink analyst Thomas Smith initiated coverage of Altimmune (NASDAQ:ALT) with an "Outperform" rating and a $10 price target. This follows positive 48-week results from Altimmune's IMPACT Phase 2b trial for its MASH drug candidate, pemvidutide, which demonstrated significant improvements in cardiometabolic measures and was well-tolerated. The company's dual GLP-1/glucagon receptor agonist shows promise for metabolic and liver diseases, attracting strong analyst confidence.
By Ramit SethiJul 05, 2026